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ABSTRACT 
Monoclonal antibodies have shown promising results as therapeutic agents, and 
yet they can also be associated with adverse side effects due to activity outside the 
disease site. Aiming to reduce these side effects, we have explored the possibility of a 
tunable antibody, whose activity can be manipulated via the addition of a small molecule. 
Previously, we incorporated a single cavity-forming mutation (tryptophan to glycine) into 
an antibody, and observed reduced antigen-binding activity that could be restored by 
addition of a complementary ligand (indole) — albeit with binding affinity too low for 
potential therapeutic applications. 
Here, I describe a novel computational strategy for enumerating larger cavities in 
a fluorescein-binding single-chain variable fragment (scFv), leading to a designed variant 
with three large-to-small mutations (triple mutant) at the domain-domain interface with 
reduced antigen-binding. Through a complementary virtual screen, we identified a 
rescuing small molecule (JK43) that enhances binding affinity for antigen. Thorough 
characterization of this system shows that the loss of activity upon mutation was due to 
loss of stability and domain dissociation; conversely, addition of JK43 restores stability 
of the antibody fragment, induces domain re-association, and rescues antigen binding. 
Beyond this initial model system, I will also describe the transferability of this 
design (triple mutant and JK43) from the fluorescein-binding scFv onto an unrelated scFv 
that shares the same three residues used in this design. We hypothesize that this design 
will also prove transferable onto the many therapeutic antibodies that also share these 
three residues, including Ipilimumab (anti-CTLA-4), Atezolimumab (anti-PD-L1), 
Nivolumab (anti-PD-1) and Adalimumab (anti-TNF-α).  
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Chapter I.  
Introduction 
The emerging use of biologics in medical treatment has been dramatic in recent 
years, and amongst FDA-approved biologics therapeutic antibodies make up the largest 
portion (1). To date, there have been more than 30 FDA-approved antibody-derived drugs 
marketed for cancer treatment (2, 3). These anti-cancer antibodies can be grouped 
broadly by the nature of their antigens, such as antibodies that target soluble proteins, 
surface antigens expressed on cancer cells, or receptors on effector cells (4). 
A class of cancer targets that have attracted considerable attention is the immune 
checkpoint family, immune system regulators that plays a role in immunological 
tolerance. Here, the immune system is capable of recognizing and responding to certain 
substances but chooses to remain tolerant to these substances, and thus the body makes 
use of this system to differentiate self from non-self, and preventing autoimmunity (5, 6). 
The discovery of the first immune checkpoint family member, cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), has deepened our understanding of an underlying 
mechanism by which cancer cells can exploit this system to evade T-cell mediated cell 
death, posing as a “self” (i.e. non-cancer) cells (7-10). This understanding spurred 
development of the first immune checkpoint inhibiting therapeutic monoclonal antibody, 
Ipilimumab, which is designed to prevent cytotoxic T-cells from recognizing cancer cells 
as “self” and is approved for metastatic melanoma treatment in 2011 (11). 
Since then, more immune checkpoint proteins have been discovered and targeted 
for cancer treatment. One pair of immune checkpoint proteins that currently occupy the 
limelight are programmed cell death protein 1 (PD-1) expressed on the surface of 
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activated T-cells, B cells and macrophages (12) and its binding partner programmed 
death-ligand 1 (PD-L1) that is often upregulated on the cancer cell surface (13-15). These 
two proteins are the targets of multiple new immune checkpoint inhibiting monoclonal 
antibodies, including FDA-approved drugs Atezolizumab (16) and Nivolumab (17) that 
have been shown to prolong overall survival in patients with non-small cell lung cancer 
(16, 17). Although the immune checkpoint inhibitors mentioned above have shown 
promising early indications, they are also associated with severe, and sometimes fatal, 
adverse side effects (18-21), largely due to the non-specific activation of T-cells (22). 
The ability to selectively blockade immune checkpoints, and thus localize immunological 
responses to the tumor environment, will be an important step in advancing therapeutic 
antibodies for safer cancer therapies. 
Allosteric protein switches: a proposed approach for limiting toxicity of therapeutic 
antibodies 
The use of chemical biology to modulate protein activity is a powerful strategy 
that can be used to engineer small molecule-dependent protein activity into specific 
proteins of interest. By tethering protein activity to the presence of a small molecule, one 
can switch “on and off” the protein using those small molecules. This scheme, if applied 
to therapeutic antibodies, may help reduce adverse side effects caused by activity of 
checkpoint inhibitors outside the tumor microenvironment. By re-engineering an 
allosteric site into therapeutic antibodies, we envision that the antibody can be produced 
in an “off state” by default, such that administering of this inactive form of the antibody 
would not trigger an immune response. Upon introduction of the activating small 
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molecule into the intended (tumor) site, the antibody will be activated and thus elicit 
toxicity only in the proximity of the injection site (Figure 1.1). 
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Figure 1.1: Model of locally-activated therapeutic antibodies. We envision that a 
therapeutic antibody could be systemically administered to a patient in an inactive form. 
An allosteric (small molecule) activator would then be administered locally, which in 
turn would activate the antibody only in this vicinity. Thus, antibody activity could be 
restricted to a specific region of the body, for example a tumor microenvironment. We 
further envision that the ability to connect antibody activity to the presence of a specific 
ligand will enable additional future refinements, such as using pro-drug forms of the 
rescuing ligand for enhanced precision with respect to spatial and temporal control.  
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Typical Approaches for Constructing Allosteric Switches 
Most conventional methods used to create allosteric switches take advantage of 
proteins harboring naturally-occurring allosteric domains that change conformation upon 
binding to their binding partners. Such domains are used as “input domains” and fused to 
some “output domain” (harboring a readout or effector function), in a process called 
domain insertion (23). In order to achieve productive interdomain coupling upon binding 
of the allosteric activator, the proper arrangement of the two domains is critical. To pair 
new combinations of input-output domains, circular permutation is commonly employed 
to identify the optimal fusing point between the input and output domain, and very large 
numbers of potential insertion sites are explicitly screened (23-26). 
Alternatively, a “split strategy” has also been used to create allosteric switches. In 
this case, the output domain is split into two halves, and each half of the output domain is 
fused onto a different part of the input domain (27). When the input domain is in its apo 
conformation, the two halves of the output domains are kept apart and are thus inactive. 
Upon addition of the effector ligand, the input domain undergoes a conformational 
change that brings the two halves of the output domain into close proximity with one 
another, thus restoring their activity. 
The main challenges for these conventional strategies are in the rational design of 
allosteric coupling (the detailed mechanism of activation). To date, the accuracy of 
structure-based models for recapitulating precise conformational changes upon small 
molecule binding are still limited. For this reason, conventional methods still rely heavily 
on explicit (wetlab) screening in order to assemble the various components of the system 
into a working allosteric switch. 
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Chemical Rescue of Structure 
As an alternative approach, we have drawn inspiration from the observation that 
internal cavities formed from mutations can be filled by the binding of hydrophobic small 
molecules (28). We have previously used our approach, “chemical rescue of structure”, to 
introduce allosteric manipulation of protein activity (29-31). Rather than relying on 
naturally occurring allosteric domains, chemical rescue of structure can be used to 
engineer allosteric sites into an arbitrary protein domain. Briefly, this method identifies a 
structurally-critical residue located in the interior of the protein of interest (a 
“buttressing” residue), and substitutes a smaller residue in its place. This mutation 
destabilizes the protein, and induces residues around the mutation site to adjust and fill in 
the resulting hydrophobic void; in doing so, the resulting conformational change can 
affect the geometry of the active site, and thus result in loss of activity. In a subsequent 
step, this mutation can be complemented with an exogenous small molecule that binds 
selectively and non-covalently to the pocket created by the mutation. If the ligand is 
carefully chosen to mimic the original sidechain that was removed upon mutation, it can 
move the surrounding residues precisely back to their original (WT) conformations, and 
thus restore protein activity. 
This approach has an advantage over conventional approaches, in that the precise 
mechanism of inactivation and rescue is not required to predict the loss and subsequent 
recovery of activity. Chemical rescue of structure, instead, relies on the ability to predict 
loss and recovery of protein stability upon small molecule binding, and protein stability is 
then used to predict loss or gain of activity (29). 
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To date, chemical rescue of structure has been demonstrated by using indole to 
rescue designed tryptophan-to-glycine (W→G) substitutions. This strategy has been 
applied successfully in two different enzymes (30, 31), a fluorescent protein (29), a 
transcription factor (29), and more recently, in an antibody (32). In each case, however, 
the opportunity to deploy the resulting switches for any real application was prevented by 
the fact that millimolar concentrations of indole were needed to recover protein activity. 
For the goal of modulating the activity of therapeutic antibodies described earlier, for 
example, it is not feasible to introduce millimolar concentrations of indole into a patient. 
Attempts to explore indole analogs, in search for a rescuing small molecule with tighter 
binding affinity, did not result in a rescuing ligand with significant improvements in 
binding affinity but rather showed that none of these rescued better than indole itself (31, 
32). We surmise that the high concentration of indole needed to activate these designed 
switches arises due to indole’s low molecular weight, which in turn limits the potentially 
attainable binding affinity (33). 
With respect to a therapeutic antibody, and an scFv fragment in particular, I 
envision a scenario in which mutations at the domain-domain interface could destabilize 
this interface such that the two domains dissociate, and thus this protein no longer binds 
to antigen. Upon addition of a complementary ligand, the two domains would then re-
associate in precisely the orientation needed for recognition of antigen, restoring activity 
(Figure 1.2). 
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Figure 1.2: Schematic of design strategy. Mutations on the light and heavy chain 
interface lead to dissociations of the domain-domain interface, which leads to loss of 
antigen binding activity. Subsequent addition of exogenous rescuing ligand (JK43) 
induces re-association of the domain-domain interface, and thus restores activity.  
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In the following chapter, I describe a computational strategy for enumerating 
larger cavities that arise from multiple simultaneous large-to-small mutations at adjacent 
buried sites, and its application to a model scFv. This mutation is then complemented by 
a larger rescuing ligand, which binds with higher affinity than any of our earlier designs. 
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Chapter II.  
Computational Design of an Allosteric Antibody Switch 
Design Strategy 
To improve the binding affinity of the activating ligand, we sought to move 
towards a small molecule with higher molecular weight. The cavity formed from a single 
W→G mutation would be too small to accommodate a ligand much larger than indole, 
thus necessitating extension of our approach to use multiple (simultaneous and adjacent) 
cavity-forming mutations instead of just one. 
Although my end goal is to engineer switchable variants of immune checkpoint 
inhibiting antibodies, producing monoclonal antibodies (mAbs, a standard antibody 
format used for therapeutic antibodies) and assays checkpoint inhibition are too 
expensive and time-consuming for a first proof-of-concept study. For this reason, I have 
instead selected a fluorescein-binding scFv (4D5Flu) as a first model system. This 
construct can be conveniently expressed in E. coli (as compared to production of 
monoclonal antibodies made in mammalian hybridomas), and 4D5Flu’s antigen, 
fluorescein, is a dye that allows for convenient monitoring of binding. 
Prior to this study, the cavity-forming mutation used in chemical rescue of 
structure could be manually selected by identifying tryptophan residues in the protein of 
interest. In the current study, where we are trying to create a larger cavity from multiple 
residue mutations, an issue arises because there is a much larger number of possible 
mutations that one could make. We therefore developed a collection of criteria for 
defining allowed sets of mutations: 
1) The mutations must together remove at least 12 heavy atoms from the protein. 
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2) At least one mutated residue must be aromatic. 
3) All mutated residues must be located at the interface between the two domains 
of the scFv. 
4) None of the mutated residues can be located on the CDR loops. 
5) We will consider only double- and triple-mutants. 
6) The mutated sidechains must be in close proximity to one other, so that the 
resulting cavity will be contiguous. 
Even with these criteria in place, there remain a vast number of possible combinations to 
test. To address this, we developed a computational approach for collecting and 
considering them. 
We began by writing an application in the Rosetta macromolecular software suite 
that implements the above criteria. The program loops over pre-defined cavity-forming 
mutations for all 2- and 3-residue groups, and upon finding a set of mutations that 
matches the criteria listed above it exports the spatial coordinates of the atoms that would 
be deleted by the mutation. We call this output a “constellation” of atoms, because this 
precise three-dimensional arrangement of atoms is what we will subsequently seek to 
mimic using a small molecule (Figure 2.1A). 
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Figure 2.1: Computational design of antibody switch. (A) Groups of two/three cavity-
forming mutations are exhaustively considered, in order to identify those located in the 
domain/domain interface that would yield a suitable cavity for subsequent rescue by a 
drug-like small molecule. (B) For each drug-like compound in the ZINC12 database, 
energetically favorable three-dimensional conformations were generated. (C) For each 
constellation of atoms that could be deleted from the protein domain/domain interface, 
every conformation of every compound was considered as a potential structural match. 
(D) The top-scoring structural matches were refined in the context of the (mutant) protein 
environment, and the top-scoring designs after re-ranking were experimentally 
characterized.   
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Applying this strategy to the 4D5Flu scFv yielded a collection of 826 unique 
constellations – each of these is the outcome of a distinct double/triple mutant, because 
each mutant removes a specific set of atoms from the scFv’s domain-domain interface. 
Each constellation was used as a template to virtually screen for small molecules that best 
complement the corresponding cavity formed. In search for small molecules that best 
recapitulate each of the 826 unique constellations, after virtual screening, it is necessary 
that we could acquire the hit compounds from these databases for experimental 
validation. 
Even though larger chemical libraries do exist, we specifically picked ZINC12 
database (34), a library of commercially-available small molecules. We further curated 
ZINC12 using the following criteria: 
1) Must follow Lipinski’s rule of 5 (35) 
2) Must have molecular weight ≥ 180 Da 
3) Must not be a pan-assay interference compound (PAINS) (36-38) 
4) Must not contain chemically-reactive groups (39, 40) 
Applying these filters reduced the size of ZINC12 from over 20 million entries down to 
~3 million entries. 
Entries in the ZINC12 database are “flat” chemical structures, rather than 3D 
structures. In order to use these for screening against the 3D constellations, it was 
therefore necessary to generate several low-energy 3D models for each of the curated 
ZINC12 entries. We carried out this step using the OMEGA application (41), generating 
up to 100 energetically-favorable 3D models (“conformers”) for each of the 3 million 
 14 
curated ZINC12 entries. All of these conformers were then compiled together to create a 
3D conformer library (300 million conformers total) (Figure 2.1B). 
Next, we used the ROCS application (42) to compare each of the 826 
constellations against each of the 300 million conformers in an all-versus-all manner. 
Each of these 2.5 billion comparisons (overlays) consisted of a fast alignment step, 
followed by a scoring step. This scoring step includes consideration of both 3D shape 
complementarity and conservation of chemical features (e.g. position of hydrogen bond 
donor/acceptors, aromatic rings, etc.) between the template (constellation) and the query 
molecule (conformers) (Figure 2.1C). 
For these candidate ligands to rescue activity, they must bind to the designed 
cavity in the active (WT) conformation of the protein. Due to the nature of constellations, 
which are combinations of atoms from different sidechains, groups of atoms in the 
constellation are not covalently connected to one another. While the rescuing ligand is 
intended to mimic the atoms in the constellation, there are inevitable differences because 
the rescuing ligand is a single entity; in particular, there are often additional atoms that 
link together the functional groups that overlap with the constellation. The extra atoms 
that comprise the linker(s), if not chosen carefully, could cause steric clashes with the 
walls of the cavity and prevent ligand binding. 
To test which of the top-scoring ligand from the ROCS alignments indeed fit 
within their cognate designed cavity, we used the ligand/constellation alignment to 
transfer the best scoring ROCS hit ligand from each constellation into the designed cavity 
and then subjected these models to energy minimization in Rosetta (Figure 2.1D). 
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After minimization, model complexes were filtered based on a combination of 
physical properties and on the similarity of the minimized complex to the WT structure, 
using the following criteria: 
1) Ligand solvent-accessible surface area (SASA) ≤ 0.13 Å2 
2) Number of rotatable bonds in the small molecule ≤ 4 
3) Numbers of buried unsatisfied polar atoms ≤ 1 
4) Ligand RMSD compared to constellation atoms ≤ 1.38 Å 
5) Backbone RMSD compared to WT ≤ 0.60 Å 
6) Ligand–cavity interaction score ≤ -10.29 Rosetta energy units (REU) 
7) Rosetta score difference compared to WT;  
a. (model of apo mutant) – (WT) ≥ 5 REU 
b. (model of holo mutant) – (WT) ≤ 5 REU 
After applying the filters, the remaining designs (cavity forming mutations and their 
cognate ligands) were ranked by their ligand-cavity interaction score. From the ranking, 
five designs were selected for experimental validation. One of these in particular (Figure 
2.2) was characterized in depth through a suite of biochemical and biophysical assays, as 
described in the following Chapter. 
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Figure 2.2: Design model of the rescued complex. (A) The crystal structure of 4D5 
(which harbors the same framework as 4D5Flu), taken from PDB ID: 1FVC. The 
location of the fluorescein antigen is modeled into this structure using a related antibody, 
PDB ID: 4NJ9. The residues that comprise our experimentally characterized triple mutant 
are indicated in blue sticks. (B) A superposition of the constellation identified through 
our computational approach, together with the ligand predicted to rescue this mutation 
(JK43, orange) shown in sticks or shown in spheres (C).   
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Methods 
Compilation of 3D Small Molecule Library 
A library of 3 million commercially-available small molecules, downloaded from 
ZINC12 (34) and subsequently curated for drug-like properties, was used as a starting 
point to create a 3D library. For each of the 3 million chemical structures, 100 low-
energy conformers were created using the OMEGA software (41), using the following 
command: 
omega2 -in input_file.smi -out output_file.sdf.gz  
-prefix ligand_name -warts -maxconfs 100 
 
Rapid Overlay of Chemical Structure 
To match constellations with specific complementary small molecules, we used 
shape-based chemoinformatic virtual screening at implemented in the ROCS software 
(OpenEye) (42). First, ROCS measures the shape overlap between template structure and 
each conformation of every compound in our library. The shape of a template molecule 
and the shape of each query molecule are aligned very rapidly using atom-centered 
Gaussian functions to maximize the overlap of volume between them. The degree of 
shape similarity between template and query is calculated using the following equation: 
𝑇𝑎𝑛𝑖𝑚𝑜𝑡𝑜!,! =
𝑂!,!
𝐼! + 𝐼! − 𝑂!,!
  
The I terms are self-volumes of each molecule, while the O term is the overlap 
between two molecules. Second, in addition to shape complementarity (ShapeTanimoto), 
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ROCS also includes an additional pharmacophoric feature (ColorTanimoto), that takes 
into account the spatial overlap of features such as hydrogen bond donors, hydrogen bond 
acceptors, and aromatic rings. It has been shown that the combination of shape and 
chemical features (TanimotoCombo) yields superior results relative to using one of the 
component scores alone (43-45). 
In our study, the template and query molecules were aligned using the following 
command: 
rocs -dbase database.sdf.gz -query query.pdb  
-prefix structure_name -cutoff -1.0 -oformat sdf -scdbase true  
-maxhits 4000 -maxconfs 4000 -outputquery false 
Rosetta Software Suite 
Extraction of constellations, refinement protein/ligand complexes, and final re-
ranking were carried out using the Rosetta software suite (46). The ROCS screen 
described above provides an alignment of a given ligand onto the template constellation. 
Since the constellation was extracted from the protein coordinates, this alignment is used 
to directly build a model of this ligand in complex with the mutant protein. The model 
was then subjected to energy minimization in Rosetta, using the following command line: 
minimize.linuxgccrelease -s input_pdb –relax:fast  
–in:file:fullatom 
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Chapter III.  
Experimental validation of switchable antibody design 
Materials and Methods 
Plasmid construction 
Because each of the two immunoglobulin domains of an scFv includes a disulfide 
bond, and we sought to express soluble scFv with the correct redox state in an E. coli 
system, we elected to add a periplasmic signal sequence at the N-terminus of the scFv. 
This extra 21-residue signal sequence is auto-cleaved during the secretion of the 
polypeptide into the periplasm (47, 48). In addition, to facilitate purification and to 
improve expression of soluble fractions, we used a vector that includes a hexa-histidine 
tag (His-tag) and a maltose binding protein tag (MBP-tag). 
The vector DNA selected for cloning was the pET PPL His6 MBP LIC cloning 
vector (2K-T), purchased from QB3-Berkeley Core Research Facilities (Addgene 
plasmid # 37183). In addition to the features described above, this vector also contains a 
tobacco etched virus protease cleavage site (TEV-site) between the three tags and our 
gene of interest. This vector was originally designed for Ligase Independent Cloning 
(LIC), but due to the emerging popularity and low failure rates of Gibson Assembly (49), 
it has been adapted for cloning with the latter approach. 
Empty vector was transformed into an NEB® Turbo Competent E. coli (High 
Efficiency), plated in a LB agar plate with 100 µg/mL ampicillin, incubated overnight at 
37 °C. A single colony from the plate was picked and grown in 50 mL of LB broth with 
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100 µg/mL carbenicillin, incubated with shaking at 250 RPM, overnight at 37 °C. 
Plasmid DNA from liquid culture was isolated according to protocol provided from 
manufacturer (QIAprep Spin Miniprep Kit, QIAGEN). Next, the empty vector DNA was 
linearized using SspI-HF® (NEB), reaction performed according to protocol provided by 
the manufacturer and linearized vector was gel purified from a 0.8% agarose gel using a 
QIAquick Gel Extraction Kit (QIAGEN). 
As for insert DNA, WT and mutant genes were synthesized in a double-stranded 
linear DNA fragment format (GeneArt Strings DNA Fragments, ThermoFisher). The WT 
amino acid sequence was obtained from a previous published study (50). These genes 
were prepared for Gibson Assembly by adding the following sequence to the 5’-end of 
the sense strand and antisense strand, respectively: 
Sense  5’- TACTTCCAATCCAATGCA-3’  
Antisense  5’- TAATAACATTGGAAGTGGATAA-3’ 
DNA strings were supplied in lyophilized vials and were reconstituted with 
molecular biology grade water. 
Gibson assembly of the linearized 2K-T empty vector and prepared inserts were 
carried out by mixing 2 µL of vector (65 ng/µL) with 8 µL of insert (100 ng/µL), then 
10 µL of Gibson Assembly® Master Mix (NEB) was added to the insert/vector mixture. 
Gibson assembly reaction was allowed to occur at 50 °C for 15 minutes, then cooled 
down to 4 °C. Reaction mixture was used to transform into a NEB® Turbo Competent 
E. coli (High Efficiency) and plated using the same protocol mentioned above. Three 
colonies from each transformation were picked and plasmid DNA prepared with the same 
protocol mentioned above, an aliquot of the plasmid DNA was sent out for successful 
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cloning verification, using Sanger sequencing. The primer set used for Sanger sequencing 
were T7 and T7-term. 
T7   5’-TAATACGACTCACTATAGGG-3’ 
T7-term  5’-GCTAGTTATTGCTCAGCGG-3’ 
Protein expression 
scFv genes in 2K-T plasmids were transformed into E. coli BL21 (DE3) 
Competent (NEB) using the protocol suggested by the manufacturer and plated 
accordingly. A single colony was obtained from the plate and inoculated into a starter 
culture, 200 mL of TB broth, 0.4% glycerol, 100 µg/mL carbenicillin and incubated with 
shaking at 250 RPM, overnight at 37 °C. Starter culture was inoculated into the main 
culture (using the same media as starter culture), with the ratio of 1:20 dilution. Main 
culture was grown with shaking at 200 RPM, at 37 °C, until O.D. reached 0.8 (measured 
at 600 nM), temperature then lowered to 15 °C and isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM, culture was 
left shaking for 48 hours. Cells were harvested by centrifugations at 3,500xG for 20 
minutes. Used media was discarded and cell pellet’s surface was rinsed with sterile 
ddiH2O (pass this point, all samples were kept at 4 °C at all times). Cells were then 
resuspended in PBS buffer (6 mM phosphate buffer, 150 mM NaCl, pH 7.4) and applied 
trough a French Press for 3 rounds. Cell lysate was spun down at 15,000xG for 30 
minutes and supernatant (which contains soluble scFv) was filtered through a 0.22-
micron PES syringe filter.  
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Protein purification 
First, cell lysate was purified with Capto L resin (GE Healthcare) by flowing 
lysate through the column (flow rate 1 mL/min) using an ÄKTA pure FPLC system (GE 
Healthcare). Column was washed using PBS until UV signal reached baseline level. 
Column was eluted using 15 mM NaOH with eluted fractions directly collected into a 
tube containing 1M sodium citrate, pH 8.0 (5% of fraction volume). Fractions containing 
scFv with higher than 70% purity was pooled and concentrated down to 50 mL and 
dialyzed against 50 mM sodium phosphate, 500 mM NaCl, 5 mM imidazole, pH 8.0 for 3 
rounds. 
Second, 5 mL of TEV protease 0.1 mg/ml was added to the dialyzed sample in the 
dialysis bag. The dialysis bag was then moved into a TEV reaction buffer 50 mM sodium 
phosphate, 500 mM NaCl, 5 mM imidazole, 2 mM DTT (freshly prepared) pH 8.0 and 
left to dialyze for 4 hours before moving the bag into a fresh batch of the same buffer and 
left to dialyze overnight. Samples were then dialyzed against 50 mM sodium phosphate, 
500 mM NaCl, 5 mM imidazole, pH 8.0 for 3 rounds to remove DTT.  
Third, samples were then applied though a Dextrin Sepharose® (GE Healthcare) 
column (flow rate 1 mL/min) using an ÄKTA pure FPLC system (GE Healthcare). Flow-
through fractions were collected and was then passed through a Ni Sepharose HisTrap FF 
(GE Healthcare) to remove TEV protease. Again, the flow-through fractions were 
collected; at this stage scFv are about 90% pure. 
Finally, samples were then concentrated down to 2.5 mL and filtered through a 
0.22-micron PES syringe filter. Next, the filtered samples were purified using a Superdex 
75 size exclusion column (GE Healthcare), using 50 mM sodium phosphate, 500 mM 
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NaCl, 5 mM imidazole, pH 8.0 buffer. Purified samples were then dialyzed into PBS, 
aliquoted into smaller volumes, then flash frozen with liquid nitrogen and stored 
at -80 °C for further use. 
Fluorescence quenching 
For the protein titration experiment, samples were prepared by titrating varying 
concentrations of protein (WT or triple mutant) into PBS containing a final concentration 
of 10 nM fluorescein and 1% DMSO, with or without 100 µM JK43. For the JK43 
titration experiment, samples were prepared by titrating varying concentrations of JK43 
into PBS with a final concentration of 10 nM fluorescein, 1% DMSO and 500 nM protein 
(WT or triple mutant). For the SAR experiment, samples were prepared by adding JK43 
analogs (to a final concentration of 10 µM) into PBS with a final concentration of 10 nM 
fluorescein, 1% DMSO and 500 nM triple mutant. 
Fluorescence quenching experiments were carried out in a SpectraMax i3x Multi-
Mode Microplate Reader (Molecular Devices), using a Costar 96-well black round 
bottom plates, 200 µL reaction volume, excitation wavelength of 475 nm and emission 
wavelength of 525 nm, at a temperature of 27 °C. Blank measurements containing all 
sample components except fluorescein were subtracted to remove background. All 
samples were normalized to a control of fluorescein alone (0% quenching) and buffer 
alone (100% quenching). 
MTPS quenching was monitored in the same manner as fluorescein quenching 
except for using MTPS instead of fluorescein, 400 nM triple mutant anti-MTPS antibody, 
and using excitation wavelength 375 nm, and emission wavelength 435 nm. 
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Thermal shift assay 
Differential scanning fluorimetry experiments were carried out in a 
QuantStudio™ 6 Flex Real-Time PCR System (ThermoFisher), using a 384-well white 
round bottom plate, 20-30 µL reaction volume, excitation wavelength of 580 nm and 
emission detected using ROX filter setting (623 nm). Samples were prepared in PBS with 
5 µM protein, 5x SYPRO Orange (ThermoFisher), and 1.1% DMSO with or without 
100 µM JK43. The scFv melting curve was collected from 25-95 °C (0.5 °C/min) and 
data were analyzed with PRISM 6 (GraphPad) using the Gibbs-Helmholtz equation (51). 
Samples were run in 8 replicates. 
NMR studies 
NMR spectra were recorded at 20 ºC on a Bruker Avance II 600 MHz NMR 
instrument equipped with a TCI triple-resonance cryogenic probe. The protein sample 
was dissolved in PBS buffer (6.1 mM phosphate buffer, 154 mM NaCl, pH 7.4), at a 
concentration of 100 µM. 
NMR data were collected using the Bruker standard pulse sequences 
hsqct1etf3gpsi3d and hsqct2etf3gpsi3d (52), then were analyzed using TopSpin 3.2 
(Bruker, USA). The T1 and T2 relaxation times were determined both by fitting peak 
intensities of the biggest peak at ~8.3 ppm, and by integrating between 7-10 ppm 
(covering most amide proton peaks) as a function of 11 relaxation delay intervals (T1: 
0.02, 0.05, 0.1, 0.2 0.3, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.5s, and T2: 1, 2, 3, 4, 5, 6, 8, 10, 12, 
15, 20s) (53) based on: 
𝐼(!) =  𝐼(!) + 𝑃𝑒
(!!!!
) 
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𝐼(!) =  𝑃𝑒
(!!!!
) 
The Igor Pro software (WaveMetrics, USA) was used to calculate the T1 and T2 
relaxation times. 
 
Results 
JK43 rescues fluorescein binding of the 4D5Flu triple mutant 
4D5Flu is an anti-fluorescein scFv that was generated by grafting the CDR loops 
from 4-4-20 (anti-fluorescein Fab) (54, 55) onto a humanized anti-HER2 scFv scaffold 
called 4D5 (50). The two halves of 4D5Flu are connected with a 30-residue linker 
(Gly4Ser)6. Out of the five multi-residue cavity-forming mutations constructs generated 
from the computational pipeline, one construct (VLF98G/VHV37A/VHW110G) was 
further characterized in-depth, this construct will be referred to as “triple mutant”, from 
this point onwards (Figure 2.2). We expressed and purified WT and triple mutant scFv 
and tested the fluorescein-binding activity (quenching) of both constructs. 
Binding by 4D5Flu quenches the fluorescence signal from fluorescein; we took 
advantage of this property to monitor the quenching activity. In the absence of activating 
ligand, the triple mutant showed diminished quenching relative to WT (Figure 3.1A). 
Upon addition of 100 µM JK43, activity of the triple mutant is restored nearly to that of 
WT (Figure 3.1A). 
The rescue of fluorescein quenching in the triple mutant exhibited dose-
dependency with an EC50 of 16 µM (Figure 3.1B). In order to verify that the rescued 
quenching activity was not due to direct fluorescein quenching by JK43, we next titrated 
 26 
increasing concentrations of either WT or triple mutant protein into a sample with no 
JK43 or with a fixed concentration of JK43 (100 µM) (Figure 3.1C). It is evident that the 
presence or absence of JK43 does not affect WT binding curve, whereas addition of JK43 
shifts the binding curve of the triple mutant closer that of the WT curve. 
In summary, then, we find that collectively introducing these three mutations 
leads to partial loss of antigen-binding activity for this scFv, and that this activity can be 
rescued through addition of JK43. These observations are consistent with the original 
model underlying our design strategy (Figure 1.2). 
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Figure 3.1: JK43 rescues activity of the 4D5Flu triple mutant. (A) Relative to WT 
4D5Flu, the designed triple mutant shows diminished quenching of fluorescein 
fluorescence. Upon addition of 10 or 100 µM JK43, activity of the triple mutant was 
partially rescued. (B) Addition of JK43 rescues fluorescence quenching of the triple 
mutant in a dose-dependent manner, with an EC50 of 16 µM. (C) Protein titrations in the 
presence or absence of 100 µM JK43. All data are presented as mean ± SEM, n = 8.   
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JK43 stabilizes the triple mutant in the presence of antigen 
From previous examples of chemical rescue of structure, we observed that 
alteration of the protein thermostability could lead to inactivation and rescue (29, 32). We 
therefore used differential scanning fluorimetry (DSF) to examine the effect of this triple 
mutation on thermostability. SYPRO Orange dye has higher fluorescence intensity when 
bound to exposed hydrophobic parts of proteins, and thus it provides a probe for proteins’ 
thermal unfolding (56-58). 
For both the WT and the triple mutant, we used DSF to monitor the thermal 
unfolding transition that results from increasing temperature. Both unfolding curves were 
fit using the equation from (51), resulting in a melting temperatures (Tm) of 56.2 °C and 
44.0 °C, respectively (Figure 3.2A). 
Upon addition of 5 µM fluorescein (equimolar to protein concentration, and far 
above the dissociation constant for this interaction), both the WT and the triple mutant 
show elevated Tm, indicating that bound fluorescein stabilizes the folded protein 
(Figure 3.2B). In contrast, addition of 100 µM JK43 (without fluorescein) destabilizes 
both the WT and the triple mutant (Figure 3.2C). The change in Tm for the WT scFv 
(which lacks a designed binding site for JK43) suggests that this compound is 
destabilizing the protein through a non-specific mechanism, presumably by making the 
solvent more non-polar and thus stabilizing exposure of the protein’s hydrophobic 
sidechains. The fact that the triple mutant is similarly destabilized suggests that the 
binding site for JK43 is not present, presumably because the protein does not adopt the 
necessary conformation in the absence of fluorescein. 
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To test this, we next monitored unfolding in the presence of both fluorescein 
(5 µM) and JK43 (100 µM). Under these conditions the WT construct was slightly 
stabilized, but less than the effect observed with fluorescein alone (Figure 3.2D). In 
essence, these two ligands appear to act independently on the WT construct, in their own 
competing directions. By contrast, addition of the two ligands together stabilizes the 
triple mutant more than fluorescein alone. Put another way, JK43 can stabilize the triple 
mutant, but only if it is in a conformation appropriate for antigen binding. In this case, 
our interpretation is that addition of fluorescein at a concentration far above the 
dissociation constant reverses the conformational change resulting from introducing the 
triple mutation, and thus pre-orders the designed binding site for JK43. This explains why 
addition of JK43 is destabilizing for the fluorescein-bound WT construct, but stabilizing 
for the triple mutant. 
Collectively, these findings point to positive cooperativity between antigen 
binding and JK43 binding in the triple mutant construct. Our fluorescence quenching 
experiment demonstrated that JK43 enhanced the triple mutant’s binding affinity for 
antigen, and here we demonstrate the converse: the presence of antigen enhances binding 
of JK43. 
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Figure 3.2: JK43 rescues thermal stability of the 4D5Flu triple mutant only in the 
presence of fluorescein. (A) The apparent thermal unfolding temperature (as measured 
via differential scanning fluorimetry), for WT 4D5Flu and for the designed triple mutant. 
(B) Upon addition of 5 µM fluorescein (at a concentration far above the dissociation 
constant), both WT and the triple mutant show increased thermal stability. (C) Upon 
addition of 100 µM JK43 (without fluorescein), both WT and the triple mutant show 
decreased thermal stability. (D) In the presence of both fluorescein and JK43, both WT 
and the triple mutant show increased thermal stability. However, the increase in stability 
of the triple mutant extends beyond that observed upon addition of fluorescein alone, 
while the increase in stability of the WT is less than that observed upon addition of 
fluorescein alone. All data are presented as mean ± SEM, n = 8. 
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JK43 enhances the interaction between the two scFv domains 
Next, we sought to directly test the structural basis for rescue of activity, by 
characterizing protein conformational changes in the triple mutant associated with 
addition of JK43. To do so, we produced uniformly 15N labeled triple mutant protein and 
measured longitudinal (T1) and transverse (T2) 15N relaxation times at 20 °C. In a stacked 
plot of the first spectra of T1 relaxation (delay of 0.02 s) of the triple mutant with and 
without the presence of equimolar JK43 (100 µM), the spectra are dominated by three 
large peaks around 8.1-8.4 ppm (Figure 3.3A). These peaks mainly arise from glycine 
and serine residues in the linker, as evidenced by their large intensities and their positions 
in the 15N HSQC spectrum (Figure 3.3B). Addition of JK43 results in a 3.4-fold increase 
in peak intensity (signal to noise ratio is 31 for the protein alone, and 104 upon addition 
of JK43). While longitudinal T1 15N relaxation times remain nearly unchanged between 
the triple mutant with and without JK43, the calculated transverse T2 15N relaxation times 
are significantly increased after the addition of JK43; this observation is consistent for T2 
values obtained both from the calculations based on peak intensity of the glycine residues 
in the linker (largest glycine peak around 8.3 ppm) and from calculations that integrate 
values between 7-10 ppm (Table 3.1). 
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Figure 3.3: Addition of JK43 induces compaction and ordering of the linker in the 
4D5Flu triple mutant. (A)  1D NMR spectra of T1 relaxation measurements at 0.02 s 
relaxation delay, for the 4D5Flu triple mutant alone (in blue) and upon addition of 
100 µM JK43 (in red). The spectrum shows three dominant peaks in the 8.1-8.5 ppm 
range, based on their intensities and positions in the 1H-15N HSQC spectrum below it we 
infer that these correspond to the glycine and serine residues in the scFv’s synthetic 
linker. (B) A portion of the 2D 1H-15N HSQC spectrum of the 4D5Flu triple mutant in 
the presence of 100 µM JK43. 
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Sample Peak Intensity T1 T2 T1/T2 
Apo ~8.29 ppm 0.864±0.155 18.336±0.477 0.0471 
1:1 ~8.28 ppm 0.825±0.026 22.789±0.421 0.0362 
1:1.5 ~8.27 ppm 0.875±0.015 23.456±0.353 0.0373 
     
 Integrate T1 T2 T1/T2 
Apo 7~10 ppm 1.034±0.148 15.869±0.477 0.0652 
1:1 7~10 ppm 0.909±0.053 18.277±0.717 0.0497 
1:1.5 7~10 ppm 0.995±0.106 20.186±0.257 0.0493 
 
Table 3.1: NMR relaxation parameters. 
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For rigid protein molecules, in the limit of slow molecular motion (τc >> 0.5 ns) 
in high magnetic field (500 MHz or greater), it has been known (52, 53, 59) that a closed 
form solution for τc as a function of T1/T2 15N relaxation times exists: 
𝜏! =
1
4𝜋𝜈!
6
𝑇!
𝑇!
− 7 
And according to the Stokes-Einstein equation: 
𝜏! =
4𝜋𝜂α!
3𝑘𝑇  
Where νN is nuclear frequency, η is viscosity, k is Boltzmann constant, T is 
temperature, and α is hydrodynamic radius. Thus, increasing T1/T2 reflects an increase in 
τc, and an increase in τc reflects an increase in α. 
With this interpretation, our observation of decreased T1/T2 upon addition of JK43 
suggests that upon binding, this ligand reduces the scFv’s hydrodynamic radius and its 
rotational correlation time. Additionally, we note that the peaks in the glycine and serine 
region of the HSQC spectrum (Figure 3.3B) become narrower upon addition of JK43 
than the corresponding peaks in the spectrum of protein alone: this suggests increased 
uniformity of the linker as JK43 induces the protein to become more compact. 
Overall, these results are consistent with a model in which the two domains 
comprising the scFv are dissociated from one another in the triple mutant, and then 
associate in response to addition of JK43. Because residues involved in antigen 
recognition are distributed across the CDR loops of both domains, this explains loss and 
then recovery of antigen binding upon mutation and subsequent rescue (Figure 1.2). 
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Structure-activity relationship of the rescuing ligand 
From our previous studies of (W→G) substitutions, we observed that indole 
(corresponding exactly to tryptophan’s sidechain) provided the most effective rescue of 
activity; however, we also observed that other ligands yielded partial rescue, with rank 
order commensurate with their similarity to indole (31, 32). These studies provided 
motivation for selection of JK43 as a complement for this particular triple mutant: we 
anticipated that an optimal rescuing ligand would closely recapitulate the three-
dimensional shape and chemical features of deleted atoms in the original protein structure 
(i.e. our constellation), and this formed the basis for our computational virtual screening 
approach. 
To test this hypothesis, we used a series of JK43 analogs to explore how varying 
the structure of the ligand would affect recovery of antigen binding in this particular 
triple mutant. Given that the two ring systems in JK43 are intended to separately mimic a 
deleted phenyl ring (from VLF98G) and an indole ring (from VHW110G), we split the 
JK43 structure in half: the left side consists of the phenyl ring and the ether linker, while 
the right side is comprised solely of the indole ring. We identified and purchased a series 
of JK43 analogs that vary either the left side of the compound, the right side, or both 
(Figure 3.5A). 
We then tested the degree to which each of these compounds rescues activity of 
the triple mutant, using the fluorescence quenching assay described earlier. At a 
concentration of 10 µM, we find that none of the analogs recovers fluorescein binding to 
the same extent as JK43 itself (Figure 3.5B). This observation is consistent with our 
model in which the rescuing ligand precisely binds to the cavity left by the cavity-
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forming mutations (Figure 1.2). Further, this observation supports the utility of detailed 
structure-based modeling for identifying suitable ligands for a given cavity: our 
underlying hypothesis was that an optimal ligand would be one that precisely matches the 
three-dimensional arrangement of the deleted atoms, and the activity of JK43 relative to 
these close analogs supports this hypothesis.  
  
 38 
 
 
Figure 3.5: JK43 rescues activity of the 4D5Flu triple mutant more effectively than 
its chemical analogs. (A) The chemical structure of JK43 (black). Several analogs were 
selected for characterization by varying JK43’s left side / linker (green), by varying 
JK43’s right side (blue), or by varying both halves (orange). (B) At a concentration of 
10 µM, JK43 rescues fluorescence quenching of the triple mutant more effectively than 
any of these chemical analogs. All data are presented as mean ± SEM, n = 8.  
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Transferability of this designed switch 
A further important consequence of this hypothesis is that JK43 should also serve 
as a suitable rescuing ligand for the corresponding mutation in other antibodies (or at 
least, scFv’s), provided they share the three deleted sidechains in precisely the same 
arrangement as in 4D5Flu. We therefore searched for the deleted constellation of atoms 
across a pair of antibody databases. 
Starting with AbYsis (60), a database of antibody sequences, we find that all three 
residues comprising this constellation are present in 63% of the 150,697 total entries 
(Figure 3.6A). Among antibodies with solved structure, as collected in the SAbDab 
database (61), we find that 78% of the 3,179 entries have this constellation in precisely 
the same geometry as 4D5Flu (Figure 3.6B). Next, we extracted the constellations from 
the subset of SAbDab that has all 3 residues conserved; we then aligned these 
constellations against the original constellation from 4D5Flu using ROCS and found out 
that most are superposable. The fact that this constellation is so strongly conserved 
among antibody sequences and structures implies that – if transferrable – this triple 
mutant coupled with JK43 may serve as a very general means to modulate activity of 
scFv’s, without the need to repeat the computational design calculations for (most) 
individual antibodies of interest. 
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Figure 3.6: Conservation of the designed constellation across antibody databases. 
(A) In the antibody sequence database AbYsis, 63% of all entries harbor the three 
residues used in the designed constellation (VLF98, VHV37 and VHW110). (B) In the 
antibody structure database SAbDab, 78% of all entries harbor these three residues in 
precisely the same conformation as in 4D5Flu  
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To test the transferability of our design, we selected another model scFv that 
shares this constellation. For ease of testing we chose another dye-binding scFv, this one 
raised to recognize 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS) as its antigen. 
Although both fluorescein and MTPS are fluorescent dyes, their chemical structures are 
quite different (Figure 3.7A). More importantly though, the scFv’s that recognize these 
antigens are very different, sharing only 56% sequence identity outside of the serine-
glycine linker (Figure 3.7B). Unsurprisingly, given their different antigens, the CDR 
loops in both scFv’s differ in both their lengths and their conformations (Figure 3.7C). 
Despite these differences, however, both share the precise arrangement of the key 
residues that comprise our constellation (Figure 3.7D), suggesting that the anti-MTPS 
scFv can also be modulated using precisely the same mutation/ligand pairing that we 
have already characterized using 4D5Flu. 
To test this hypothesis, we generated the same triple mutant in the context of this 
anti-MTPS scFv, and used MTPS quenching as a measure of scFv binding. In the absence 
of JK43 this mutant scFv quenches MTPS with an EC50 value of 1.0 µM; upon addition, 
however, the EC50 value is reduced to 0.1 µM (Figure 3.7E). Thus, our studies of this 
mutation/ligand pair in the context of 4D5Flu allowed us to rapidly generate an 
analogous switch in an unrelated antibody, by virtue of this structurally-conserved 
constellation. These results confirm that indeed this mutation/ligand pairing is indeed 
transferrable, provided that the scFv of interest harbors these conserved residues in 
precisely the same geometry as in 4D5Flu. 
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Figure 3.7: JK43 rescues activity of the corresponding triple mutant in an unrelated 
scFv. (A) The chemical structures of the two antigens of the characterized scFv’s, 
fluorescein and MTPS. (B) The amino acid sequence alignment of 4D5Flu and the anti-
MTPS scFv. The three residues that comprise the conserved constellation is highlighted 
with black boxes. (C) Despite their sequence divergence, these two scFv’s have the same 
overall architecture. The structure of the anti-MTPS crystal structure (salmon) (PDB ID: 
4NJ9) is aligned to the framework structure of 4D5Flu (light blue) is drawn from the 
crystal structure of the parent antibody, 4D5 (PDB ID: 1FVC). (D) Despite their 
sequence divergence, these two scFv’s also have precisely the same structural 
arrangement of the sidechains that comprise the deleted constellation. (E) Monitoring 
MTPS quenching allows determination of the scFv’s binding affinity in the presence or 
absence of JK43. In the absence of JK43, the anti-MTPS triple mutant quenches MTPS 
with EC50 1.0 µM. Upon addition of 100 µM JK43 the EC50 is improved ten-fold, to 0.1 
µM. All data are presented as mean ± SEM, n = 8.  
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Chapter IV.  
Discussion and Future Steps 
As a first step towards avoiding toxicity associated with therapeutic antibodies 
acting outside the desired spatial region, we have designed a method to control antibody 
activity using chemical biology. 
The first study reporting allosteric control of antibody activity directly engineered 
allosteric sites into the CDR loop (H3) of an anti-fluorescein antibody, and demonstrated 
regulation of antigen-binding upon addition of Zn2+ (62). This method has several 
drawbacks. First, the fact that the effector molecule (Zn2+) is not bio-orthogonal 
precludes this strategy from being used for spatiotemporal control of an antibody in 
therapeutic settings. Second, the system lacks selectivity, as demonstrated by partial 
activation of the antibody in the presence of other divalent ions. 
By contrast, envisioning future therapeutic applications, we were determined to 
create an allosteric antibody switch that would be both bio-orthogonal and selective. 
Looking back at our own previous work, we noted that chemical rescue of structure has 
been demonstrated as an alternative approach used to engineer allosteric protein switches, 
by connecting protein activity to the presence of an activating small molecule (29-31). As 
preparation for the current study, we also applied chemical rescue of structure in an 
antibody setting, by showing that the activity of the mutant antibody (FITC-E2 VH 
W118G) was restored upon addition of indole – albeit with an EC50 of 220 µM (32), too 
high for potential therapeutic applications. 
Here, to overcome the shortcomings of the single W→G design, we have 
expanded our strategy to include multiple-cavity forming mutations and screen a large 
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library of commercially-available compounds for re-activating small molecules. We have 
shown that addition of JK43 rescues the stability, structure, and conformational dynamics 
of the triple mutant: together, these rescue the scFv’s affinity for antigen. Through the 
findings reported herein, we have shown that the mechanism of inactivation and rescue is 
modulated through changes in antibody stability, in agreement with many of our previous 
studies in assorted model systems (29, 31, 32). The present study is also consistent with 
results from previous model systems in that alternate ligands exhibit diminishing extents 
of rescue as the potential rescuing ligand become more dissimilar to the rescuing ligand 
that best fits the engineered cavity (29, 31, 32). 
As hypothesized, we found that using a larger rescuing ligand (and by necessity, 
engineering a larger cavity into the protein) led to an improvement in binding affinity: 
JK43 has an EC50 of 16 µM, as compared to 220 µM from indole. That said, we also 
anticipated that designing a larger cavity into the protein would reduce the background 
antigen binding (i.e. binding prior to addition of the rescuing ligand): we found this not to 
be the case. Moving forward, we plan to introduce additional destabilizing mutations 
designed to shift the equilibrium of the apo mutant scFv further towards the inactive 
state. 
Already in these studies we have demonstrated the transferability of this design 
(triple mutant and JK43) from a fluorescein-binding antibody into an MTPS-binding 
antibody, even though the two antibodies only share 56% sequence identity. This shows 
that the overall sequence identity, in general, is less relevant to the transferability of the 
design, as long as the three residues that comprise this constellation are conserved in the 
antibody of interest. With respect to therapeutic antibodies already in the clinic, this 
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particular constellation/ligand pairing could find application in a number of candidates: 
among these, Ipilimumab (anti-CTLA-4, PDB ID: 5XJ3), Atezolimumab (anti-PD-L1, 
PDB ID: 5X8L), Nivolumab (anti-PD-1, PDB ID: 5GGR) and Adalimumab (anti-TNF-α, 
PDB ID: 3WD5). We did a structural alignment, comparing crystal structures of these 
four therapeutic antibodies against the crystal structure of our design framework, and 
confirmed that all three residues in the triple mutant design are superposable (Figure 
4.1). We do note, however, that to date we have only tested this design in an scFv 
construct; further development may be necessary to use this approach in a Fab or IgG 
context, in which the dissociated (mutant) variable domains may be more restricted by 
the presence of the constant regions. 
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Figure 4.1: Triple mutant constellation is conserved in FDA-approved therapeutic 
antibodies. (A) Despite their sequence divergence, all 4 therapeutic antibodies 
(Ipilimumab (anti-CTLA-4, PDB ID: 5XJ3), Atezolimumab (anti-PD-L1, PDB ID: 
5X8L), Nivolumab (anti-PD-1, PDB ID: 5GGR) and Adalimumab (anti-TNF-α, PDB ID: 
3WD5)) have the same overall architecture with the framework structure of 4D5Flu 
drawn from the crystal structure of the parent antibody, 4D5 (PDB ID: 1FVC). (B) 
Despite their sequence divergence, all 5 antibodies also have precisely the same structural 
arrangement of the sidechains that comprise the deleted constellation.   
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Thinking ahead, the use of a small molecule to control activity of a therapeutic 
antibody has unique advantages over traditional modalities. First, as compared to small 
molecule drugs, this approach maintains the tight and selective binding of therapeutic 
antibodies to avoid off-target interactions. At the same time, though, the fact that 
antibody activity relies on the presence of the small molecule activator allows for 
potential spatiotemporal control in new ways – including the fact that decay of activity 
may be determined by clearance of the small molecule, which is expected to have more 
rapid pharmacokinetics than the antibody. 
In order to enhance this system beyond the capabilities of the current scheme, I 
envision drawing further from the chemical biology toolbox in two ways. First, additional 
spatial control could be achieved by exploiting unique conditions of the tumor 
microenvironment to further help reduce off-site activation of antibodies. This could be 
achieved through a pro-drug approach (63), in which labile protective groups are added to 
the activating ligand that prevent it from fitting into the designed cavity. Factors present 
in the tumor microenvironment, such as specific matrix metalloproteases, would then 
cleave the protecting group to reveal the original activating ligand. Second, to enhance 
the effective binding affinity of the rescuing ligand, I envision adapting the rescuing 
ligand such that it binds covalently to the designed antibody. This could be achieved by 
using site-specific non-natural amino acid incorporation (64) to introduce a bio-
orthogonal and bio-compatible “clickable” group into the designed cavity (65, 66), and 
then providing the complementary functional group on the activating ligand. Together, I 
envision these two future developments will allow additional selectivity and sensitivity 
surpassing those of the current designed allosteric switch.  
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